A normal adult heart is composed of several different cell types, among which cardiac mesenchymal stromal cells represent an abundant population. The isolation of these cells offers the possibility of studying their involvement in cardiac diseases, and, in addition, provides a useful primary cell model to investigate biological mechanisms.
Introduction
Mesenchymal Stromal Cells (MSC) are adult cells with an important supportive function in many tissues 1 . Bone marrow represents the historical source of MSC, but they can be isolated from different tissues including placenta, adipose tissue, cord blood, liver, and heart 1, 2 .
In 2006, the International Society for Cellular Therapy (ISCT) specified, for the first time, the minimal criteria to define human MSC 3 . In particular, MSC must have the ability to adhere to plastic. They express specific surface antigens: the positivity for CD44, CD105, CD29, and CD90 mesenchymal markers, and the negativity for CD14, CD45, CD34, CD31 hematopoietic and endothelial markers characterize MSC. Due to the lack expression of HLA-DR, MSC are unable to trigger alloreactivity. Moreover, they are multipotent cells with the potential to differentiate toward adipogenic, chondrocyte, and osteoblast lineages 1, 3 .
Focusing on cardiac cellular composition, cardiac mesenchymal stromal cells (C-MSC) are abundant in a normal adult heart 4, 5 . They play a critical role both in the normal cardiac function and pathological conditions. While, physiologically, C-MSC provide a microenvironment that supports the structural and functional integrity of the myocardium, in heart diseases they are activated in response to heart injury participating in the wound healing and fibrotic remodeling 6, 7 .
Recently, the involvement of C-MSC in arrhythmogenic cardiomyopathy (ACM) adipose substitution has been demonstrated 8 . In particular, ACM is a genetic disorder mainly caused by mutations in desmosomal genes that lead to myocardial fibro-fatty replacement, mainly in the right ventricle
Solutions
1. Make TMES medium for C-MSC culture with Iscove's Modified Dulbecco's Medium (IMDM), supplemented with 20% Fetal Bovine Serum (FBS), 10 ng/mL basic fibroblast growth factor, 10,000 U/mL Penicillin, 10,000 µg/mL Streptomycin, and 0.02 M L-Glutamine. Filter the TMES medium using a 0.22 µm sterile filter unit, and store at 4 °C. 2. To prepare collagenase solution, resuspend the collagenase NB4 mix in IMDM medium to obtain a final solution with a concentration of 3 mg/mL. Vortex gently to dissolve the powder, and filter the collagenase solution using a 0.2 µm syringe filter. Aliquot 1 mL volume into 2 mL sterile tubes and store at -20 °C until needed for use. 3. To prepare T. ADIPO medium, make adipogenic medium with IMDM medium supplemented with 10% FBS, 0.5 mM 3-isobutyl-1-methylxanthine (pre-diluted in dimethyl sulfoxide (DMSO) at a concentration of 0.5 M and kept at -20 °C until use), 1 µM hydrocortisone (prediluted in DMSO at 100 mM and further diluted to 10 mM in sterile distilled water and kept at -20 °C until use) and 0.1 mM indomethacin (prediluted in DMSO at a concentration of 0.5 M and kept at -20 °C until use). Filter the T. ADIPO medium using a 0.22 µm sterile filter unit and store at 4 °C. 4. Prepare washing buffer composed of phosphate-buffered saline 0.0067 M PO 4 (PBS), ethylenediamine tetra acetic acid (EDTA) 5 mM, and 5% bovine serum albumin, and store at 4 °C. 5. Prepare oil red O (ORO) working solution by dissolving 1% ORO powder in 60% isopropanol, mixing for 2 h, and filtering using a 0.22 µm filter unit to remove precipitates. Store the working solution at room temperature (RT).
1. When the cells are 80% confluent, transfer the digested small bioptic samples into a new sterile 60-mm tissue culture treated plate, and add 3 mL of fresh TMES medium. Note: The bioptic samples can be re-used for further C-MSC isolation. It is possible to repeat this procedure until there is a significant number of isolated cells. 2. Wash the attached cells twice with 3 mL of sterile PBS. Add trypsin-EDTA solution (0.5 mL for a 60-mm dish), and incubate at 37 °C for 3 -5 min to allow cell detachment. 3. When the cells are detached from the surface of the plate, add 0.5 mL of sterile FBS to inactivate the trypsin and collect cells into a new 50 mL sterile tube. 4. Wash the plate twice with 5 mL of sterile PBS to add the remaining cells to the same tube. 5. Centrifuge the cells at 400 x g for 10 min at RT. 6. Remove the supernatant and resuspend the pellet in 1 mL of TMES medium. 7. Load 10 µL of the cell suspension in the cell counting chamber.
Note: If the cells are too concentrated, dilute the initial suspension 1:10 in PBS and load 10 µL of the diluted cells in the cell counting chamber. 8. Under the microscope, count cells in 3 large squares and on the lines of two of their sides and calculate the average number of cells.
Note: To obtain the number of cells/mL, the average of counted cells is multiplied by 10 4 , the dilution factor of the cell counting chamber. If the cells have been further diluted, multiply for the dilution factor. The ratio between the cell number to seed and the cell concentration (number of cells/mL) corresponds to the volume (in mL) of initial suspension to be plated for the next step (point 3.9). 9. Plate the resuspension onto sterile 100-mm tissue culture treated plates at a final concentration of 5,000 -10,000 cells/cm 2 and add TMES medium to the final volume of 8 mL. Incubate the plate in a cell culture incubator. Note: Repeat the cell expansion procedure when the cells are 70 -80% confluent. At every passage (P), it is recommended to cryopreserve part of the cells and plate the remaining amount. Expand the cells until P3 or P4 and use for fluorescent-activated cell sorter (FACS) analysis (section 4) and adipogenic differentiation (section 5). 10. For the cryopreservation after detachment, centrifuge the cells at 400 x g for 10 min at RT. 11. Count cells as described (steps 3.7 -3.8) and resuspend 1 x 10 6 cells in 900 µL of sterile FBS. Transfer to a sterile cryo-vial and add 100 µL of sterile DMSO and mix. 12. Quickly store the cryo-vials into a freezing container at -80 °C for at least 2 days and then transfer the vials into liquid nitrogen.
Characterization of Cardiac Mesenchymal Stromal Cells by Flow Cytometry
Note: Before starting, make sure to have the cell dissociation reagent, washing buffer, and the specific antibodies prepared.
1. When the cell number reaches at least 3 x 10 6 (count the cells as described in 3.7 -3.8), wash the 100-mm plate twice with 10 mL of sterile PBS. 2. Add 5 mL of a cell dissociation reagent and wait 7 -10 min at RT to allow the cell detachment. 3. When the cells are detached from the surface of the plate, add 15 mL of sterile washing buffer and collect the suspension into a new 50 mL sterile tube. 4. Wash the plate twice with 10 mL of washing buffer and add the remaining cells to the same tube. 5. Centrifuge the cells at 400 x g for 10 min at RT and resuspend the pellet in 1 mL of washing buffer. 6. Count the cells as described (steps 3.7 -3.8), and transfer 3 x 10 6 cells into a new sterile tube and add washing buffer to the final volume of 1.5 mL.
Note: The total cell number and the total volume of washing buffer depends on the number of selected markers used for the analysis (3 x 10 5 cells in 100 µL for each FACS polystyrene tube). 7. Distribute 100 µL of cellular suspension in 12 different FACS polystyrene tubes, and add the specific antibody at the concentration indicated in the product datasheet. Note: Antibodies used for C-MSC characterization are CD34, CD105, CD45, CD29, CD90, CD44, CD31, CD14, and HLA-DR ( Table 1) . It is important to prepare a control sample composed of 100 µL of resuspended cells stained with the isotype control to check the specificity of the signal. 8. Incubate the samples for 15 min in the dark. 9. Add 1 mL of sterile washing buffer to each tube to stop the reaction. 10. Centrifuge the cells at 400 x g for 10 min at RT. 11. Remove the supernatant and resuspend the pellet in 250 µL of washing buffer. 12. Proceed to C-MSC characterization with flow cytometry.
Adipogenic Differentiation of Cardiac Mesenchymal Stromal Cells
Note: Before starting, make sure to have prepared T. ADIPO medium and ORO working solution. . Different studies have been performed to isolate and characterize them for potential applications in basic and translational research 12, 13 .
In healthy conditions, MSC are quiescent, self-renewing at low rates 14 . Since they are exposed to environmental pathological changes, they react fostering tissue remodeling through either direct transdifferentiation, matrix deposition, or the paracrine effect 14 .
The cardiac MSC (C-MSC) represent a large non-myocyte cell population of the heart 4 . They originate from the epicardium and migrate into the myocardium undergoing the process of epithelial-to-mesenchymal transition 15 . They contribute to the mechanical and electrical integrity of the cardiac structure, both in physiological and in pathological states, through interactions with cardiomyocytes and extracellular matrix homeostasis 7, 16 . However, the broad range of C-MSC functions is still not completely understood. A deeper knowledge of their role both in physiological and pathological conditions can be facilitated by in vitro studies performed after their isolation. C-MSC have been obtained from different districts of the human heart, such as the atrial appendage 2,17 and right ventricle 18 .
Recently, C-MSC from human right ventricular endomyocardial bioptic samples have been obtained 8 , demonstrating that the source tissue could be as little as 3-5 mg.
Possible applications:
The method outlined in this manuscript allows obtaining cells with few simple passages, such as digestion and selection for plastic adherence, from very small heart specimens.
C-MSC can be considered a cell model, since they are easy to amplify and maintain in vitro, and are able to differentiate into cells of mesenchymal lineage (endothelium, osteocytes, and adipocytes). Moreover, the possibility of obtaining cells directly from patients constitutes a great in vitro tool for mechanistic studies in the context of personalized/precision medicine. Indeed, these cells carry the genetic background and eventually specific mutations of the donors, and are influenced by the specific patients' characteristics, such as clinical conditions, age, sex, lifestyle, and medications. Moreover, the possibility of sorting them for different markers may allow the study of specific C-MSC subsets 19 . C-MSC are known to be active players in different cardiovascular diseases, mostly characterized by adverse remodeling of the heart. Therefore, they represent candidate targets for novel therapeutic strategies to counteract heart diseases 8, 20 . C-MSC stem-like properties and their lack of significant immunogenicity suggests their potential application in cell-therapy for cardiac regenerative medicine. Indeed, like MSC from bone marrow or other sources, C-MSC could be potentially used both in autologous and in allogenic settings, without the need for matching between donor and recipient 21 .
Moreover, C-MSC, being isolated directly from heart tissue, have the advantage of being preconditioned by the cardiac micro-environment and epigenetic profile. In the context of cardiac regenerative medicine, this could be particularly important to obtain successful results.
To date, preclinical studies of regenerative medicine identified useful therapeutic potential in the C-MSC and their paracrine activity 18, 22, 23 . Importantly, clinical trials in which the cell source is the heart are underway either with cardiosfere-derived cells or with subpopulations of C-MSC 13, 24, 25 . Their myocardium is gradually substituted by scar-tissue, an electrically inert tissue composed of adipocytes and fibrosis. In order to guide the bioptic sampling to the scar area, where the diagnostic yield is maximal, endomyocardial mapping is used 10, 28, 29 . The samples used in this protocol are taken in the border zone of the diseased myocardium.
Sommariva et al. has recently defined a pivotal role of C-MSC in the pathogenesis of ACM 8 , demonstrating that C-MSC are active players in ACM heart adipogenesis, since preadipocytes in those hearts are of mesenchymal origin. Moreover, C-MSC isolated with the present protocol from ACM patients' biopsies showed more propensity to both lipid accumulation and adipogenesis than controls. For this reason, these cells could be used to confirm some of the molecular mechanisms of ACM, proving their suitability as a cell model for mechanistic studies 9 .
Limitations and critical steps: Despite the advantages of obtaining C-MSC directly from patients (see the paragraph "Possible applications"), this protocol is subjected to different limitations.
First of all, the cardiac bioptic procedure is invasive and often avoided if not strictly necessary. Indeed, sampling cardiac tissue is both ethically and technically problematic. Reasons for performing a cardiac biopsy may be the achievement of a definite diagnosis in the context of cardiomyopathies in differential diagnosis, monitoring the status of cardiac transplants, or ascertaining the presence of a heart tumor 30 . Therefore, only patients for which an endomyocardial biopsy is indicated by consensus statement 31 can be enrolled for research on C-MSC.
Moreover, the cardiac bioptic procedure can have clinical complications, above all in cardiomyopathic hearts. Therefore, electrophysiologist's samplings are always cautious and bioptic samples could be very small, compromising the isolation of cells. Future experiments could overcome this issue by tuning collagenase concentration or timing of digestion.
C-MSC, as all primary human cells, show a high variability among different subjects in all phenotypes. Indeed, cells from different subjects are not only genetically different, but also subjected to variable environmental conditioning. Specifically, within this experiment, a high variability in cell isolation, growth, and adipogenic differentiation is observed.
Critical steps of the present protocol have to be acknowledged. If the bioptic sample includes capillaries, they must be removed to avoid the parallel isolation of endothelial cells, which may contaminate the C-MSC culture, and can be evidenced by the FACS analysis (positivity for CD31). To obtain an efficient adipogenic differentiation, cells must be in an active growth phase. The degree of confluence may also influence lipid accumulation.
Significance of the method: With respect to previous methods of isolation of mesenchymal stromal cells, this is the first time where the description of C-MSC obtainment directly from human ventricular bioptic samples is proposed in detail. Although this method is suggested for the processing of ACM patient samples, it is potentially applicable to all the patients for which a cardiac biopsy is indicated.
This protocol represents a useful implementation of previous methods for the obtainment of cells that required bigger cardiac samples 32 , which are often difficult to collect.
Moreover, the sample source constitutes an interesting innovation. While the ventricular biopsy is usually performed on the septum 33 , this protocol takes into account samples obtained from the right ventricular free wall. Cells derived from the diseased right ventricular district may be more representative of the pathologic status of diseases involving RV.
In addition, some of the reagents used in the present protocol are different with respect to other C-MSC isolation and differentiation methods 32 . For example, the type of collagenase proposed in this manuscript is a mix of class I and class II collagenases with a balanced ratio of proteolytic activities. Moreover, the digestion solution is composed of the collagenase mix dissolved in the same basal medium (IMDM) used for the preparation of C-MSC culture medium, allowing isolated C-MSC to adapt to future growth conditions. In addition, though sorting procedures could standardize the cell batch, using the whole C-MSC population, isolated only through the plastic adherence property of these cells, constitutes a simplification without altering the immunophenotypic characteristics of C-MSC. The composition of T. ADIPO proposed in this manuscript is able to lead to adipogenic differentiation, avoiding the metabolic dysregulation induced by other components such as insulin.
Moreover, the proposed method of lipid accumulation quantification, which is based on the evaluation of the ORO colorimetric intensity, provides more information about the quantity of the accumulated lipids, if compared with methods based only on the percentage of cells positive to the ORO staining. Often lipid accumulation is quantified by extracting the ORO incorporated by cells with isopropanol and measuring its absorbance. However, this method requires more passages and is subjected to variability due to isopropanol evaporation.
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